Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Stagezero Life Sciences Ltd (SZLS.TO)

Stagezero Life Sciences Ltd (SZLS.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Stagezero Life Sciences Ltd 70 East Beaver Creek Road Unit 30 Richmond Hill ON L4B 3B2 CAN

P: 905-209-2030

Description:

StageZero Life Sciences Ltd is a Canadian company, focused on developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and personalized health management, with a primary focus on cancer-related indications. It develops a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. Its lead product, ColonSentry is a blood test to determine the patient's current risk of having colorectal cancer.

Key Statistics

Overview:

Market Capitalization, $K 29,572
Shares Outstanding, K 78,858
Annual Sales, $ 4,152 K
Annual Net Income, $ -6,864 K
Last Quarter Sales, $ 405 K
Last Quarter Net Income, $ 4,330 K
60-Month Beta 0.79
% of Institutional Shareholders 0.18%

Growth:

1-Year Return -63.33%
3-Year Return -21.87%
5-Year Return -87.66%
5-Year Revenue Growth 66.36%

Per-Share Information:

Next Earnings Date 08/20/21
Earnings Per Share ttm -0.11
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year -5.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-8 on 09/18/20

SZLS.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward 3.71
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % -125.82%
Profit Margin % -165.32
Net Margin % -1.03
Debt/Equity 1.67
Price/Sales 2.49
Price/Book 45.30
Book Value/Share 0.01
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar